Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 3552.02 | 653 / 653 | 100% | 8.42 | 602 / 605 |
breast | 100% | 4215.42 | 459 / 459 | 99% | 8.39 | 1112 / 1118 |
lung | 100% | 4915.78 | 578 / 578 | 98% | 6.36 | 1132 / 1155 |
prostate | 100% | 2403.60 | 244 / 245 | 98% | 5.02 | 492 / 502 |
bladder | 100% | 2459.81 | 21 / 21 | 96% | 5.01 | 483 / 504 |
kidney | 100% | 2078.88 | 89 / 89 | 96% | 8.59 | 862 / 901 |
uterus | 100% | 3366.43 | 170 / 170 | 95% | 5.39 | 438 / 459 |
adrenal gland | 100% | 2174.64 | 257 / 258 | 95% | 5.31 | 219 / 230 |
skin | 97% | 1449.67 | 1762 / 1809 | 97% | 9.39 | 456 / 472 |
brain | 94% | 1109.44 | 2479 / 2642 | 100% | 9.34 | 705 / 705 |
pancreas | 95% | 1255.35 | 313 / 328 | 98% | 6.83 | 174 / 178 |
intestine | 100% | 2922.74 | 965 / 966 | 92% | 4.40 | 483 / 527 |
esophagus | 99% | 2087.55 | 1433 / 1445 | 92% | 5.12 | 169 / 183 |
stomach | 99% | 1887.65 | 355 / 359 | 92% | 4.92 | 264 / 286 |
ovary | 100% | 1994.85 | 180 / 180 | 89% | 3.81 | 382 / 430 |
liver | 99% | 1523.71 | 223 / 226 | 84% | 3.78 | 342 / 406 |
adipose | 100% | 4843.62 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 13.66 | 29 / 29 |
spleen | 100% | 11541.87 | 241 / 241 | 0% | 0 | 0 / 0 |
heart | 100% | 2028.41 | 860 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 6948.07 | 924 / 929 | 0% | 0 | 0 / 0 |
muscle | 99% | 1823.93 | 796 / 803 | 0% | 0 | 0 / 0 |
blood vessel | 98% | 1823.95 | 1308 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 93% | 5.05 | 42 / 45 |
eye | 0% | 0 | 0 / 0 | 80% | 4.11 | 64 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006919 | Biological process | activation of cysteine-type endopeptidase activity involved in apoptotic process |
GO_1900226 | Biological process | negative regulation of NLRP3 inflammasome complex assembly |
GO_0051607 | Biological process | defense response to virus |
GO_0032691 | Biological process | negative regulation of interleukin-1 beta production |
GO_0043280 | Biological process | positive regulation of cysteine-type endopeptidase activity involved in apoptotic process |
GO_0032088 | Biological process | negative regulation of NF-kappaB transcription factor activity |
GO_0032731 | Biological process | positive regulation of interleukin-1 beta production |
GO_0042981 | Biological process | regulation of apoptotic process |
GO_0097264 | Biological process | self proteolysis |
GO_0031665 | Biological process | negative regulation of lipopolysaccharide-mediated signaling pathway |
GO_0140633 | Biological process | CARD8 inflammasome complex assembly |
GO_0006915 | Biological process | apoptotic process |
GO_0097340 | Biological process | inhibition of cysteine-type endopeptidase activity |
GO_0043122 | Biological process | regulation of canonical NF-kappaB signal transduction |
GO_0010804 | Biological process | negative regulation of tumor necrosis factor-mediated signaling pathway |
GO_0043124 | Biological process | negative regulation of canonical NF-kappaB signal transduction |
GO_0140374 | Biological process | antiviral innate immune response |
GO_0072559 | Cellular component | NLRP3 inflammasome complex |
GO_0032991 | Cellular component | protein-containing complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0140634 | Cellular component | CARD8 inflammasome complex |
GO_0005634 | Cellular component | nucleus |
GO_0050700 | Molecular function | CARD domain binding |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0008233 | Molecular function | peptidase activity |
GO_0038187 | Molecular function | pattern recognition receptor activity |
GO_0008656 | Molecular function | cysteine-type endopeptidase activator activity involved in apoptotic process |
GO_0032089 | Molecular function | NACHT domain binding |
GO_0140693 | Molecular function | molecular condensate scaffold activity |
GO_0140608 | Molecular function | cysteine-type endopeptidase activator activity |
GO_0005515 | Molecular function | protein binding |
Gene name | CARD8 |
Protein name | Caspase recruitment domain family member 8 CARD8 protein CARD8 isoform T51 Caspase recruitment domain-containing protein 8 (EC 3.4.-.-) (CARD-inhibitor of NF-kappa-B-activating ligand) (CARDINAL) (Tumor up-regulated CARD-containing antagonist of CASP9) (TUCAN) [Cleaved into: Caspase recruitment domain-containing protein 8, C-terminus (CARD8-CT); Caspase recruitment domain-containing protein 8, N-terminus (CARD8-NT)] |
Synonyms | NDPP1 KIAA0955 DACAR |
Description | FUNCTION: Inflammasome sensor, which mediates inflammasome activation in response to various pathogen-associated signals, leading to subsequent pyroptosis of CD4(+) T-cells and macrophages . Inflammasomes are supramolecular complexes that assemble in the cytosol in response to pathogens and other damage-associated signals and play critical roles in innate immunity and inflammation . Acts as a recognition receptor (PRR): recognizes specific pathogens and other damage-associated signals, such as HIV-1 protease activity or Val-boroPro inhibitor, and mediates CARD8 inflammasome activation . In response to pathogen-associated signals, the N-terminal part of CARD8 is degraded by the proteasome, releasing the cleaved C-terminal part of the protein (Caspase recruitment domain-containing protein 8, C-terminus), which polymerizes to initiate the formation of the inflammasome complex: the CARD8 inflammasome directly recruits pro-caspase-1 (proCASP1) independently of PYCARD/ASC and promotes caspase-1 (CASP1) activation, which subsequently cleaves and activates inflammatory cytokines IL1B and IL18 and gasdermin-D (GSDMD), leading to pyroptosis . Ability to sense HIV-1 protease activity leads to the clearance of latent HIV-1 in patient CD4(+) T-cells after viral reactivation; in contrast, HIV-1 can evade CARD8-sensing when its protease remains inactive in infected cells prior to viral budding . Also acts as a negative regulator of the NLRP3 inflammasome . May also act as an inhibitor of NF-kappa-B activation . .; FUNCTION: [Caspase recruitment domain-containing protein 8]: Constitutes the precursor of the CARD8 inflammasome, which mediates autoproteolytic processing within the FIIND domain to generate the N-terminal and C-terminal parts, which are associated non-covalently in absence of pathogens and other damage-associated signals. .; FUNCTION: [Caspase recruitment domain-containing protein 8, N-terminus]: Regulatory part that prevents formation of the CARD8 inflammasome: in absence of pathogens and other damage-associated signals, interacts with the C-terminal part of CARD8 (Caspase recruitment domain-containing protein 8, C-terminus), preventing activation of the CARD8 inflammasome . In response to pathogen-associated signals, this part is ubiquitinated by the N-end rule pathway and degraded by the proteasome, releasing the cleaved C-terminal part of the protein, which polymerizes and forms the CARD8 inflammasome (Probable) . .; FUNCTION: [Caspase recruitment domain-containing protein 8, C-terminus]: Constitutes the active part of the CARD8 inflammasome . In absence of pathogens and other damage-associated signals, interacts with the N-terminal part of CARD8 (Caspase recruitment domain-containing protein 8, N-terminus), preventing activation of the CARD8 inflammasome . In response to pathogen-associated signals, the N-terminal part of CARD8 is degraded by the proteasome, releasing this form, which polymerizes to form the CARD8 inflammasome complex: the CARD8 inflammasome complex then directly recruits pro-caspase-1 (proCASP1) and promotes caspase-1 (CASP1) activation, leading to gasdermin-D (GSDMD) cleavage and subsequent pyroptosis . . |
Accessions | E5RFI5 ENST00000447740.6 [Q9Y2G2-4] ENST00000518622.5 ENST00000518979.5 ENST00000518450.5 ENST00000519332.5 [Q9Y2G2-6] ENST00000651546.1 [Q9Y2G2-5] ENST00000522773.5 ENST00000519940.6 [Q9Y2G2-5] ENST00000517510.5 H0YB90 E5RIN1 ENST00000522431.5 [Q9Y2G2-6] ENST00000521613.5 [Q9Y2G2-4] B5KVR7 ENST00000391898.7 [Q9Y2G2-5] E5RGG3 E5RJG3 ENST00000521415.5 ENST00000520753.5 [Q9Y2G2-3] ENST00000522889.5 E5RGC9 E5RHZ3 ENST00000519646.5 I6L9C6 ENST00000520153.5 [Q9Y2G2-4] E5RHJ3 ENST00000523579.5 H0YBW7 ENST00000521437.1 Q9Y2G2 ENST00000520007.5 [Q9Y2G2-6] ENST00000519302.6 ENST00000520015.5 [Q9Y2G2-3] |